Related Experiment Video

Updated: Sep 15, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K

Early initiation of sacubitril/valsartan in STEMI patients improves ventricular remodeling

Hongyuan Wang1, Yanping Wang1, Xinjun Zhang1

  • 1Department of Cardiology, Jiangshan People's Hospital Quzhou 450001, Zhejiang, China.

American Journal of Translational Research
|July 17, 2025
PubMed

Insights

Early sacubitril/valsartan treatment in ST-elevation myocardial infarction (STEMI) patients improves heart function and reduces injury markers. This approach enhances ventricular remodeling and patient prognosis without adverse effects.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • ST-elevation myocardial infarction (STEMI) is a critical condition requiring timely intervention.
  • Left ventricular remodeling significantly impacts patient prognosis post-STEMI.

Purpose of the Study:

  • To investigate the impact of early sacubitril/valsartan administration on left ventricular remodeling and prognosis in STEMI patients.
  • To evaluate the efficacy of sacubitril/valsartan compared to valsartan alone in STEMI management.

Main Methods:

  • Retrospective analysis of 150 STEMI patients.
  • Comparison of 70 patients treated with early sacubitril/valsartan versus 80 patients treated with valsartan.
  • Assessment of echocardiographic parameters and cardiac injury biomarkers.

Main Results:

  • Sacubitril/valsartan group showed improved left ventricular ejection fraction and reduced ventricular dimensions.
  • Significant reduction in cardiac injury biomarkers (BNP, Troponin) and inflammatory markers in the sacubitril/valsartan group.
  • Enhanced stroke volume and reduced left ventricular end-systolic and end-diastolic volumes observed with early sacubitril/valsartan.

Conclusions:

  • Early sacubitril/valsartan initiation in STEMI patients significantly improves ventricular remodeling.
  • Treatment leads to enhanced echocardiographic parameters and reduced biomarkers of injury and inflammation.
  • No increase in adverse events or compromise in renal function was observed.
Abstract

Keywords:
EntrestoSTEMIearly treatmentsacubitril/valsartanventricular remodeling

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.4K
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.4K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
513
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
27
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
80
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
32
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
47